GlaxoSmithKline Is Preparing To Change The Chairman Of The Board Of Directors
Press office of GlaxoSmithKline announced the imminent departure of Christopher Gent from the position of Chairman of the Board of Directors. He folded his powers on May 7, 2015 at the annual general meeting. Philip Hampton will become the new chairman.
Hampton joined the Board of Directors of GlaxoSmithKline on January 1, 2015, on April 1, he will become a deputy chairman of the governing body of the company. Also, he retained the chairman of the board of directors of Royal Bank of Scotland (RBS) until August 1, 2015.
GlaxoSmithKline became known on the upcoming reshufflein September last year. According to market experts, the appointment of a new chairman happened due to the necessity of making certain changes to the company, which was recently found guilty by a court of China in bribes and agreed to pay a fine in the amount of 489 million dollars.
- AbbVie Can Abandon The Acquisition Of Shire
- AbbVie Paid Shire 1,6 Billion For Failed Acquistion
- Abbott Can Acquire Russian Veropharm By The End Of The Year